文献速递消化道肿瘤与早癌

非甾体抗炎药使用、多基因风险评分与结直肠癌风险

Non-steroidal anti-inflammatory drugs, polygenic risk score and colorectal cancer risk.
PubMed 文献 · Aliment Pharmacol Ther · 2021-06-11

基于德国大型人群病例对照研究(5129例结直肠癌病例与4093例对照),评估规律使用非甾体抗炎药(NSAIDs)与结直肠癌风险的关系是否随多基因风险评分(PRS,基于140个风险位点)变化。结果显示规律使用NSAIDs(包括阿司匹林)与结直肠癌风险降低相关(OR 0.66,95%CI 0.59-0.74),且与PRS无交互作用(P=0.10);该效应相当于PRS降低32个百分位(GRE -32,95%CI -41至-22)。

要点

  • 规律使用NSAIDs与结直肠癌风险降低相关,OR为0.66(95%CI 0.59-0.74)。
  • 仅规律使用阿司匹林同样与风险降低相关,OR为0.73(95%CI 0.65-0.83)。
  • NSAIDs效应与PRS无交互作用,相当于PRS降低32个百分位。

核心结论

  • 规律使用NSAIDs与结直肠癌风险大幅降低相关,且该关联不随个体多基因风险谱变化。
  • 在所有多基因风险组中相对风险降低程度相当,绝对风险降低预计在高多基因风险评分者中最强。

研究设计与样本

  • 基于德国大型人群病例对照研究,纳入5129例结直肠癌病例和4093例对照。
  • 使用基于140个结直肠癌相关风险位点的多基因风险评分(PRS)量化遗传风险。
  • 采用多变量逻辑回归估计规律使用NSAIDs(≥2次/周持续至少1年)与结直肠癌风险的关联,并按PRS水平分层分析。
  • 使用遗传风险等效值(GRE)比较NSAIDs对结直肠癌风险的影响与PRS的影响。

主要发现

  • 规律使用NSAIDs(包括阿司匹林)与结直肠癌风险降低相关,OR 0.66(95%CI 0.59-0.74)。
  • 仅规律使用阿司匹林与结直肠癌风险降低相关,OR 0.73(95%CI 0.65-0.83)。
  • NSAIDs使用与PRS之间无交互作用,P值分别为0.10和0.22。
  • NSAIDs使用的效应相当于PRS降低32个百分位(GRE -32,95%CI -41至-22)。

关键数值与推荐

  • 规律使用NSAIDs定义为≥2次/周持续至少1年。
  • PRS基于140个结直肠癌相关风险位点构建。
  • 规律使用NSAIDs的OR为0.66(95%CI 0.59-0.74),仅阿司匹林的OR为0.73(95%CI 0.65-0.83)。
  • GRE为-32(95%CI -41至-22),表示NSAIDs效应相当于PRS降低32个百分位。

临床怎么用

  • 规律使用NSAIDs与结直肠癌风险降低相关,且该关联不受个体多基因风险谱影响。
  • 在高多基因风险评分人群中,NSAIDs的绝对风险降低可能更显著,可考虑个体化风险沟通。
  • GRE指标可用于向患者传达NSAIDs使用对结直肠癌风险的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The regular use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced colorectal cancer (CRC) risk. AIM: To explore whether this association varies according to background polygenic risk for CRC. METHODS: Data were collected from a large population-based case-control study on CRC in Germany. A polygenic risk score (PRS) based on 140 CRC-related risk loci was used to quantify the genetic risk. The associations of regular use of NSAIDs (≥2times per week for at least 1 year) with CRC risk were estimated in the whole population and in subgroups according to PRS levels using multivariable logistic regression. The impact of NSAIDs on CRC risk was compared to PRS using the 'genetic risk equivalent' (GRE), a recently developed metric for effective risk communication. RESULTS: In total 5129 CRC cases and 4093 controls were included in this analysis. The regular use of NSAIDs (including aspirin) was associated with reduced CRC risk [odds ratio (OR) 0.66, 95% confidence interval (CI) 0.59, 0.74], as was regular use of aspirin only (OR 0.73, 95% CI 0.65, 0.83), without indication of interaction with the PRS (P = 0.10 and 0.22 respectively). The effect of NSAID use was equivalent to the effect of having a 32 percentiles lower PRS (GRE -32, 95% CI -41, -22). CONCLUSIONS: The regular use of NSAIDs is associated with greatly reduced CRC risk regardless of individual genetic profile. With an equivalent reduction of relative risk across all polygenic risk groups, absolute risk reduction would be expected to be strongest among those with the highest polygenic risk score.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chen X, Guo F, Hoffmeister M, et al. Non-steroidal anti-inflammatory drugs, polygenic risk score and colorectal cancer risk. Aliment Pharmacol Ther. 2021. PMID: 34114659. doi:10.1111/apt.16438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。